Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ABBV-706 by AbbVie for Neuroendocrine Carcinoma: Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Neuroendocrine Carcinoma. According to GlobalData, Phase I...
ABBV-706 by AbbVie for Oligodendroglioma: Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Oligodendroglioma. According to GlobalData, Phase I drugs...
ABBV-706 by AbbVie for Glioblastoma Multiforme (GBM): Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
ABBV-706 by AbbVie for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData,...
ABBV-706 by AbbVie for Small-Cell Lung Cancer: Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
ABBV-706 by AbbVie for Solid Tumor: Likelihood of Approval
ABBV-706 is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...